by Paul Lelieveld | Jun 27, 2022 | Meneldor News
Study Designed to Evaluate Whether T-Guard is Superior to Ruxolitinib in Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease Preliminary Results Expected First Half of 2023 Results Expected to Provide the Basis for Both FDA and EMA...
by Paul Lelieveld | May 3, 2022 | Meneldor News
Hemispherian is an innovative pharmaceutical company focused on developing a novel class of small molecule drugs (GLIX). GLIX compounds target the TET2 enzyme and activate the DNA damage response resulting in cancer cell death. The company’s lead compound, GLIX1, is...
by Paul Lelieveld | Jan 10, 2022 | Meneldor News
FDA Orphan Drug Designation (ODD) underscores strength of Atriva’s pipeline and high need for treatments for rare and neglected tropical diseases ODD allows Atriva to benefit from various incentives to develop zapnometinib (ATR-002) against hantavirus infections, and...
by Paul Lelieveld | Dec 22, 2021 | Meneldor News
Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces that admission of its Ordinary Shares to trading on the AIM market of the London Stock Exchange commenced at 8:00 a.m. today, 22...
by Paul Lelieveld | Dec 2, 2021 | Meneldor News
Dr. Piet Wigerinck, former CSO of Galapagos, to strengthen Atriva’s advisory board, bringing vast experience in late-stage pharmaceutical development Frans van Dalen, Pharm D., representative of Atriva’s lead investor Meneldor, continues support for Atriva on the...
